TLR4 and metabolic dysfunction-associated steatotic liver disease: Butyrate can decrease the lipopolysaccharide (LPS) and its receptor Toll-like receptor 4 (TLR4) in the liver by repairing HFD-induced damage to the intestinal mucosa and strengthened intestinal tight junctions, which is beneficial for the treatment of NAFLD (34, 136).